CellCentric, a company co-founded with epigenetic research pioneer Professor Azim Surani of the Gurdon Institute, University of Cambridge, has secured $60 million in funding to advance the clinical testing of its novel cancer therapy. The funding round includes the conversion of a loan note from Pfizer into $25 million equity, alongside a new investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm.
The investment will enable CellCentric to complete the necessary clinical testing to meet FDA requirements in preparation for Phase III trials. Professor Surani's work focuses on the discovery and description of an epigenetic code, which exists beyond DNA and can dictate cell fate. This foundational research underpins CellCentric's therapeutic approach.
CellCentric aims to leverage its understanding of epigenetic mechanisms to develop targeted cancer therapies. The company has not disclosed specific details about the drug or its target, but the funding will be crucial in advancing its clinical development program.
